Europe
Kiadis Pharma N.V. announced the launch of a first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia with off-the-shelf Natural Killer cells manufactured using Kiadis’ FC21 mbIL21 feeder cells and proprietary universal donor platform.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Data position the company to start potential registrational trials with two drugs in two tumor types
Cellbox Solutions announces the expansion of its Board of Directors and the appointment of a new CEO - Wolfgang Kintzel will start as Chief Executive Officer effective March 1, 2020.
Bioactive Adrenomedullin is a biomarker for endothelial dysfunction and allows the prediction of septic shock as elevated blood levels of bio-ADM(R) predict blood pressure break down and blood vessel leakage resulting in edema
In its announcement, Bicycle did not identify the cancer targets it will focus on in its collaboration with Genentech.
The ASRS issued a note to its members about concerns regarding reports of vasculitis, an inflammation of the blood vessels and other complications that can lead to the loss of vision, as a potential side effect of treatment with Beovu.
The FDA is reviewing the sNDA under the Real-Time Oncology Review (RTOR) pilot program, which could speed up the process for potential approval.
Exblifep is a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime.
Pawel Rosikiewicz - co-founder of “SwissAI Machine Learning Meetups” and of the SwissAI foundation - joins GenomSys in the role of Scientific Communications Expert.
PRESS RELEASES